Outcomes of Multidrug-Resistant Tuberculosis Treatment with Early Initiation of Antiretroviral Therapy for HIV Co-Infected Patients in Lesotho

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Satti, Hind ^a,b   McLaughlin, Megan M ^a,c   Hedt Gauthier, Bethany ^b   Atwood, Sidney S ^c   Omotayo, David B ^a   Ntlamelle, Likhapha ^a   Seung, Kwonjune J ^a,c  

^a PARTNERS IN HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; CAPREOMYCIN; CYCLOSERINE; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LAMIVUDINE PLUS ZIDOVUDINE; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EARLY INTERVENTION; EPIDEMIC; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LESOTHO; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OCCUPATION; OUTCOME ASSESSMENT; PREDICTION; RISK ASSESSMENT; SOUTH AFRICA; SURVIVAL TIME; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; HUMANS; LESOTHO; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84868149994     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046943     Document Type: Article

References (40)

1. Selwyn P, Hartel D, Lewis V, Schoenbaum E, Vermund S, et al. (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320: 545-550.
2. Daley C, Small P, Schecter G, (1992) Schoolnik G, McAdam R, et al (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 326: 231-235.
3. Antonucci G, EGirardi, Raviglione M, Ippolito G, (1995) Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 274: 143-148.
4. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, et al. (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326: 1514-1521.
5. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA, (1995) Tuberculosis in New York City-turning the tide. N Engl J Med 333: 229-233.
6. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, et al. (1996) A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 276: 1229-1235.
7. Moro M, Gori A, Errante I, Infuso A, Franzetti F, et al. (1998) An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 12: 1095-1102.
8. Fischl M, Uttamchandani R, Daikos G, Poblete R, Moreno J, et al. (1992) An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 117: 177-183.
9. World Health Organization (2011) Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011 (WHO/HTM/TB/2011.3). Geneva: WHO.
10. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580.
11. Shenoi S, Heysell S, Moll A, Friedland G, (2009) Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 22: 11-17.
12. Centers for Disease Control and Prevention (2007) Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. Available: http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm. Accessed 2012 Apr 3.
13. Lawn SD, Myer L, Bekker LG, Wood R, (2007) Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21: 335-341.
14. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G, (2009) Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS ONE 4: e4520.
15. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, et al. (2007) HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 (Suppl 1): S86-107.
16. Friedland G, (2007) Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Curr Infect Dis Rep 9: 252-261.
17. Perumal R, Padayatchi N, Stiefvater E, (2009) The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa. BMC Public Health 9: 243.
18. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO.
19. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al. (2010) HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 181: 80-86.
20. Farley JE, Ram M, Pan W, Waldman S, Cassell GH, et al. (2011) Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PLoS ONE 6: e20436.
21. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N, (2010) High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 14: 413-419.
22. Munsiff SS, Ahuja SD, Li J, Driver CR, (2006) Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis 10: 639-648.
23. Palacios E, Franke M, Munoz M, Hurtado R, Dallman R, et al. (2012) HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis 16: 348-354.
24. Waisman JL, Palmero DJ, Alberti FA, Guemes Gurtubay JL, Francos JL, et al. (2001) [Improved prognosis in HIV/AIDS related multi-drug resistant tuberculosis patients treated with highly active antiretroviral therapy]. Medicina (B Aires) 61: 810-814.
25. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, et al. (2010) Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 375: 1798-1807.
26. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, et al. (2009) Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa. PLoS ONE 4: e7186.
27. World Health Organization (2011) TB data: Tuberculosis country profiles. Available: http://www.who.int/tb/country/en/index.html. Accessed 2012 Apr 3.
28. Ministry of Health and Social Welfare (2009) Demographic and Health Survey, Lesotho: Ministry of Health and Social Welfare, Bureau of Statistics.
29. USAID TB Care II (2011) Community-based care for drug-resistant tuberculosis: a guide for implementers.
30. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, et al. (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9: 640-645.
31. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM, (2009) Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 4: e6914.
32. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9: 153-161.
33. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, et al. (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359: 563-574.
34. Heller T, Lessells RJ, Wallrauch CG, Barnighausen T, Cooke GS, et al. (2010) Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 14: 420-426.
35. Centers for Disease Control and Prevention (2003) Treatment of TB, American Thoracic Society, CDC, Infectious Diseases Society of America. MMWR 52.
36. Tuberculosis Coalition for Technical Assistance (2009) International Standards for Tuberculosis Care (ISTC), Second Edition. The Hague: Tuberculosis Coalition for Technical Assistance.
37. World Health Organization (2010) Treatment of tuberculosis: guidelines- 4th edition. Geneva: WHO.
38. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348: 119-128.
39. Park HH, Girdler-Brown BV, Churchyard GJ, White NW, Ehrlich RI, (2009) Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former Basotho gold miners. Am J Ind Med 52: 901-908.
40. Basu S, Stuckler D, Gonsalves G, Lurie M, (2009) The production of consumption: addressing the impact of mineral mining on tuberculosis in southern Africa. Global Health 5: 11.